Theranos

Theranos was an American health-technology company founded by Elizabeth Holmes in 2003. It presented itself as a transformative diagnostics business whose proprietary instruments could perform a broad range of blood tests from a finger-prick or other very small sample. The promise combined medical convenience, lower testing costs, faster results, and a consumer-oriented alternative to conventional venous blood draws and centralized laboratory systems. The company initially operated under the name Real-Time Diagnostics and later adopted the name Theranos, formed from a combination of “therapy” and “diagnosis.” Holmes promoted the venture as a major technological breakthrough and recruited influential directors, investors, commercial partners, and public figures. Its profile grew particularly after it obtained substantial private financing and entered a high-profile relationship with Walgreens, which began offering Theranos testing to customers at selected retail locations in Arizona and California. Theranos’s central product story focused on the Edison and later miniLab systems, along with proprietary nanotainer collection devices. The company claimed that these systems could run many tests using only a few drops of blood. In practice, reporting by The Wall Street Journal, regulatory findings, testimony at the criminal trial, and later court proceedings established that the company frequently relied on conventional commercially available analyzers for patient testing and that its proprietary devices did not perform the wide range of tests publicly suggested. The company also faced allegations that it misled investors, patients, business partners, and regulators about the capabilities and validation of its technology. The 2015 Wall Street Journal investigation triggered a sequence of regulatory, legal, and commercial crises. The Centers for Medicare & Medicaid Services found serious deficiencies at the company’s laboratory and imposed sanctions, including a ban affecting Holmes’s ability to own or operate a laboratory for a period. Walgreens ended its relationship with Theranos, and the Securities and Exchange Commission later charged Theranos, Holmes, and Ramesh “Sunny” Balwani with raising money through extensive fraud. The company voided or corrected test results for many patients and ceased operations in 2018. Holmes and Balwani were subsequently prosecuted in federal court. Holmes was convicted in 2022 on investor-fraud counts and sentenced in 2022 to more than eleven years in prison. Balwani was convicted separately and received a thirteen-year sentence. The Theranos case became a prominent example of the risks associated with secrecy, weak technical validation, celebrity governance, aggressive fundraising, and the use of a compelling founder narrative in a highly regulated medical field. The company itself is defunct and no longer provides products or services.

Theranos began in 2003 as Real-Time Diagnostics, a company founded by Stanford University student Elizabeth Holmes. Its original concept was to make blood testing less invasive by collecting a small sample from a finger rather than drawing multiple tubes of venous blood. The company later changed its name to Theranos and developed a highly controlled corporate culture around proprietary technology and secrecy. Holmes presented Theranos as a broad diagnostics platform rather than a single medical device company. The company claimed that its instruments, initially associated with the Edison name, and its small sample-collection technology could conduct a large menu of tests rapidly and at lower cost. Theranos attracted prominent investors and directors, including senior figures from government, diplomacy, business, and the military. The board’s prestige helped reinforce the company’s public credibility, although several directors lacked deep laboratory-science expertise. The company’s most visible commercial step was its partnership with Walgreens. Beginning in 2013, selected Walgreens locations offered Theranos testing services, first in Arizona and later in California. Patients could order tests and provide samples at retail sites. The partnership gave Theranos a consumer-facing distribution channel and helped sustain the impression that its technology had reached practical deployment. The company also promoted relationships with other businesses and discussed ambitions to expand access to diagnostic testing. Behind the public narrative, employees and laboratory experts raised concerns about the performance, validation, and representation of Theranos technology. The Wall Street Journal reported in 2015 that the company performed many tests using conventional Siemens analyzers rather than its own equipment. Theranos disputed aspects of the reporting, but the disclosures prompted investigations and intensified scrutiny from regulators, medical professionals, investors, and business partners. The Centers for Medicare & Medicaid Services inspected a Theranos laboratory and identified deficiencies that threatened patient health and safety. CMS imposed sanctions, including restrictions affecting Holmes’s operation of a laboratory. The Food and Drug Administration also examined aspects of the company’s devices and practices. Walgreens suspended and then terminated its relationship, while Theranos faced lawsuits and pressure from investors and patients. The company voided or corrected a large number of test results and closed its clinical laboratories. In 2018, the SEC charged Theranos, Holmes, and president and chief operating officer Ramesh Balwani with securities fraud. The SEC alleged that they had made false or misleading statements about the capabilities of the company’s analyzers, the extent of its use by the military, its relationships with pharmaceutical companies, its financial prospects, and its commercial performance. Holmes settled the SEC case without admitting or denying the allegations, accepted financial and governance restrictions, and was barred from serving as an officer or director of a public company for a period. Balwani contested the allegations in the criminal process. Theranos announced that it was winding down in 2018 and dissolved later that year. Federal criminal trials followed. Holmes was convicted in 2022 on investor-related fraud and conspiracy counts, while the jury acquitted her on some patient-related counts and did not reach a verdict on others. She was sentenced to 135 months in prison. Balwani was convicted separately on all counts brought against him and received a 155-month sentence. The company’s rise and collapse became a widely discussed case study in corporate governance, biomedical validation, regulatory oversight, whistleblower retaliation, and the limits of founder-driven secrecy in healthcare.

1. 2022Holmes convicted

   Elizabeth Holmes was convicted on investor-fraud and conspiracy counts in federal court.

   Source
2. 2018SEC enforcement action and company dissolution

   The SEC charged Theranos and its senior leaders with fraud, and the company ceased operations and dissolved.

   Source
3. 2016Regulatory sanctions and commercial retreat

   CMS cited laboratory deficiencies, and Walgreens ended its relationship with Theranos.

   Source
4. 2015Investigative reporting exposes technology concerns

   The Wall Street Journal reported that Theranos used conventional analyzers for many tests, challenging its public claims about proprietary technology.

   Source
5. 2013Walgreens partnership announced

   Theranos and Walgreens announced a partnership intended to make Theranos testing available through selected retail pharmacies.

   Source
6. 2004Name changed to Theranos

   The company adopted the Theranos name as it developed its small-sample blood-testing business.

   Source
7. 2003Company founded as Real-Time Diagnostics

   Elizabeth Holmes founded the venture that later became Theranos, initially under the name Real-Time Diagnostics.

   Source

A medical-diagnostics venture positioned as a convenient, inexpensive, consumer-friendly alternative to conventional laboratory blood testing.

• EdisonBlood-testing analyzer

  Edison was the best-known Theranos analyzer concept. The company represented it as a compact platform capable of processing numerous clinical tests from very small blood samples. Public and regulatory scrutiny later established that the device did not perform the broad testing menu implied by Theranos’s marketing, and that conventional analyzers were used for many patient tests.

• miniLabBlood-testing analyzer

  The miniLab was a later-generation Theranos testing platform presented as a smaller and more capable successor to earlier systems. It was associated with the company’s plans for decentralized testing, but it did not reach a validated commercial role before Theranos shut down.

• NanotainerBlood-sample collection device

  Nanotainer was the name used for Theranos’s small-volume blood-collection concept. The device was intended to collect and transport a small quantity of capillary blood for analysis, supporting the company’s claim that extensive testing could be performed without conventional blood draws.

• Theranos testing servicesClinical laboratory testing2013

  Theranos offered clinical blood-testing services through its own laboratories and selected Walgreens locations. The service was marketed around convenient collection, broad test availability, and lower patient burden. Operations were terminated after regulatory findings, partner withdrawal, and legal scrutiny.

• 2014Consumer-access and small-sample testing campaign

  United States

  Theranos promoted the idea that patients could obtain a broad range of tests from a small blood sample, emphasizing convenience, speed, and reduced discomfort compared with traditional phlebotomy.

  Outcome. The positioning became central to subsequent allegations that the company had overstated the capabilities of its technology.

  Source
• 2013Walgreens retail testing rollout

  United States · Arizona · California

  Theranos used its Walgreens relationship to present blood testing as a convenient retail healthcare service and to move its technology from a private-company narrative into consumer-facing locations.

  Outcome. The rollout was curtailed after investigative reporting, regulatory scrutiny, and concerns about test accuracy and technology claims; Walgreens terminated the relationship in 2016.

  Source

• 2018Wind-down and dissolutionStrategy

  Theranos could not sustain operations after commercial partnerships collapsed and legal and regulatory pressure intensified.

  What changed. The company ceased operations and dissolved.

  Aftermath. Its remaining assets and records became connected to litigation, patient-result issues, and government enforcement proceedings.

  Source
• 2015Public defense of technology and business claimsStrategy

  Investigative reporting and employee concerns challenged the company’s representations about its analyzers and testing practices.

  What changed. Theranos publicly disputed reporting and maintained that its technology and operations were being mischaracterized while regulatory reviews proceeded.

  Aftermath. The dispute was followed by escalating regulator action, partner withdrawal, lawsuits, and the company’s eventual closure.

  Source
• 2013Pursuit of retail pharmacy distributionStrategy

  Theranos sought a rapid route to consumers rather than limiting itself to research partnerships or conventional laboratory channels.

  What changed. The company partnered with Walgreens to provide testing at selected retail locations.

  Aftermath. The relationship increased public visibility but ended after questions about the company’s technology, laboratory practices, and regulatory compliance.

  Source

• 2022Elizabeth Holmes criminal convictionControversy

  Holmes was convicted on investor-fraud and conspiracy counts and later sentenced to 135 months in prison.

  Source
• 2022Ramesh Balwani criminal convictionControversy

  Balwani was convicted in a separate federal case and later sentenced to 155 months in prison.

  Source
• 2018SEC fraud allegationsControversy

  The SEC alleged that Theranos, Holmes, and Balwani misled investors about the technology, business relationships, military use, and financial prospects of the company.

  Source
• 2016Laboratory regulatory deficienciesControversy

  CMS found serious deficiencies at a Theranos laboratory and imposed sanctions affecting the company’s laboratory operations and Holmes’s future laboratory activities.

  Source
• 2015Questions over proprietary testing claimsControversy

  Reporting alleged that Theranos used conventional laboratory analyzers for many tests while publicly emphasizing its own proprietary systems.

  Source

1. Theranos
2. SEC Charges Theranos, CEO Elizabeth Holmes, and Former President Ramesh Balwani With Massive Fraud
3. Elizabeth Holmes Convicted of Four Counts of Fraud and Conspiracy to Commit Fraud
4. Former Theranos President and Chief Operating Officer Ramesh Balwani Sentenced to 13 Years
5. Clinical Laboratory Improvement Amendments
6. Theranos Has Struggled With Technology Claims
7. Wind-down and dissolution